A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.

Autor: Poston JN; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA., Fromm JR; Seattle Cancer Care Alliance, Seattle, WA, USA.; Department of Laboratory Medicine, Division of Hematopathology, University of Washington, Seattle, WA, USA., Rasmussen HA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA., Shustov AR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA., Libby EN 3rd; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA., Smith SD; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gopal AK; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Seattle Cancer Care Alliance, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2019 Jul; Vol. 186 (1), pp. 159-162. Date of Electronic Publication: 2018 Dec 28.
DOI: 10.1111/bjh.15742
Databáze: MEDLINE